文献速递肾小球疾病

研究性RNA疗法sefaxersen靶向补体因子B治疗IgA肾病的单臂2期试验

A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy.
PubMed 文献 · Kidney Int · 2025-12-22

这项全球探索性单臂开放标签2期试验评估了补体因子B反义寡核苷酸抑制剂sefaxersen治疗IgA肾病的疗效与安全性。23例活检确诊且尿蛋白>1.5 g/d、eGFR<40 mL/min/1.73m²的患者接受70 mg每月皮下注射24周,第29周24小时尿蛋白排泄较基线降低43%至几何均值1.4 g/d,eGFR保持稳定,支持进一步开展3期IMAGINATION试验。

要点

  • sefaxersen选择性抑制补体旁路途径活性,第29周尿蛋白降低43%。
  • 治疗期间eGFR保持稳定,基线均值70.4,第29周均值73.2 mL/min/1.73m²。
  • 3例出现一过性可逆的ALT升高(3-5倍正常上限),胆红素无变化。

核心结论

  • sefaxersen抑制IgA肾病患者补体旁路途径活性并降低蛋白尿,且eGFR稳定。
  • 研究结果支持在3期IMAGINATION试验中进一步评估sefaxersen作为IgA肾病新疗法。

研究设计与样本

  • 全球探索性、单臂、开放标签2期试验(NCT04014335)。
  • 纳入23例活检确诊IgA肾病伴肾C3沉积、血尿、24小时蛋白尿>1.5 g/d且eGFR<40 mL/min/1.73m²的患者。
  • 患者每月皮下注射sefaxersen 70 mg(RO7434656),持续24周,随后可自愿参加治疗扩展。
  • 主要终点为第29周24小时尿蛋白排泄(UPE)较基线的变化。

主要发现

  • 基线蛋白尿几何均值为2.5 g/d。
  • 血浆补体FB和Bb、尿因子Ba及血清补体旁路途径活性选择性降低,经典途径活性无变化。
  • 第29周UPE降低43%至几何均值1.4 g/d,UPCR和UACR有相似降低。
  • eGFR基线均值70.4 mL/min/1.73m²,第29周均值73.2 mL/min/1.73m²,保持稳定。
  • 7例参加治疗扩展的患者蛋白尿降低持续,其中4例治疗超过12个月。

关键数值与推荐

  • 纳入标准:活检确诊IgA肾病伴肾C3沉积、血尿、24小时蛋白尿>1.5 g/d、eGFR<40 mL/min/1.73m²,且已接受最大耐受剂量RAAS阻断。
  • 主要终点:第29周24小时UPE较基线变化。
  • 给药方案:sefaxersen 70 mg皮下注射,每月一次,共24周。

临床怎么用

  • sefaxersen通过抑制补体旁路途径降低IgA肾病患者蛋白尿,eGFR保持稳定。
  • 治疗期间需监测肝功能,关注一过性可逆的ALT升高。

局限性

  • 单臂、开放标签设计,无对照组。
  • 样本量较小(23例)。
  • 随访时间较短(主要终点第29周),长期疗效和安全性有待进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Activation of the complement system and subsequent local inflammation in the kidney plays a key role in the pathogenesis of IgA nephropathy (IgAN). Here, we investigated the efficacy and safety of sefaxersen, an antisense oligonucleotide inhibitor of complement factor B (FB), for the treatment of IgAN in a global exploratory, single arm, open-label trial (NCT04014335). METHODS: Patients were included with biopsy-confirmed IgAN with kidney C3 deposits, hematuria, 24-hour proteinuria above 1.5 g/day, and eGFR under 40mL/min/1.73m2 despite maximum tolerated renin-angiotensin-aldosterone-system blockade. Patients received sefaxersen 70 mg (RO7434656) subcutaneously monthly for 24 weeks followed by voluntary treatment extension. The primary endpoint was a change in 24-hour urinary protein excretion (UPE) at week 29 compared to baseline. RESULTS: The trial enrolled 23 patients with baseline geometric mean proteinuria of 2.5 g/day. There were selective reductions of plasma complement FB and Bb, urinary factor Ba and serum complement alternative pathway activity, without changes in classical pathway activity. At week 29, UPE was reduced by 43% to a geometric mean of 1.4 g/day, with similar reductions in UPCR and UACR. Estimated GFR at baseline was mean 70.4 ml/min/1.73m2, remained stable through week 29 (mean 73.2 ml/min/1.73m2). Proteinuria reduction was sustained in all seven participants who opted to participate in the treatment extension, including four patients treated for over 12 months. There was one treatment emergent serious adverse event not related to study drug. Transient and reversible alanine amino transferase elevations (3-5X fold upper limit normal) without a change in bilirubin were observed in three individuals, who remained on study and completed treatment. CONCLUSIONS: Sefaxersen inhibited complement alternative pathway activity in patients with IgAN and reduced proteinuria with stable eGFR. Our findings support further evaluation of sefaxersen as a new therapy for IgAN in the Phase 3 IMAGINATION trial. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT04014335.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Barbour SJ, Hladunewich MA, McCaleb ML, et al. A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy. Kidney Int. 2025. PMID: 41443406. doi:10.1016/j.kint.2025.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。